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Abstract 
Background: This study aimed to evaluate whether selecting mirtazapine as the first choice for current depressive 
episode instead of selective serotonin reuptake inhibitors (SSRIs) reduces benzodiazepine use in patients with major 
depressive disorder (MDD). We concurrently examined the relationship between clinical responses and serum mature 
brain-derived neurotrophic factor (BDNF) and its precursor, proBDNF.
Methods: We conducted an open-label randomized trial in routine psychiatric practice settings. Seventy-seven MDD 
outpatients were randomly assigned to the mirtazapine or predetermined SSRIs groups, and investigators arbitrarily 
selected sertraline or paroxetine. The primary outcome was the proportion of benzodiazepine users at weeks 6, 12, 
and 24 between the groups. We defined patients showing a ≥50 % reduction in Hamilton depression rating scale 
(HDRS) scores from baseline as responders. Blood samples were collected at baseline, weeks 6, 12, and 24.
Results: Sixty-five patients prescribed benzodiazepines from prescription day 1 were analyzed for the primary out-
come. The percentage of benzodiazepine users was significantly lower in the mirtazapine than in the SSRIs group at 
weeks 6, 12, and 24 (21.4 vs. 81.8 %; 11.1 vs. 85.7 %, both P < 0.001; and 12.5 vs. 81.8 %, P = 0.0011, respectively). No 
between-group difference was observed in HDRS score changes. Serum proBDNF levels were significantly decreased 
(χ2 = 8.5, df = 3, P = 0.036) and serum mature BDNF levels were temporarily significantly decreased (F = 3.5, df = 2.4, 
P = 0.027) in the responders of both groups at week 24.
Conclusion: This study demonstrated mirtazapine as the first-choice antidepressant for current depressive episodes 
may reduce benzodiazepine use in patients with MDD.
Trial registration UMIN000004144. Registered 2nd September 2010. The date of enrolment of the first participant to the 
trial was 24th August 2010. This study was retrospectively registered 9 days after the first participant was enrolled
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Background
Benzodiazepines and benzodiazepine-like drugs such as 
zolpidem and zopiclone are widely prescribed to improve 
insomnia and anxiety symptoms in combination with 
antidepressants for the pharmacological treatment of 
major depressive disorder (MDD) [1–3]. Evidence indi-
cates that using benzodiazepines in conjunction with 
antidepressants in the first short-term treatment of MDD 
is effective [4, 5] and useful in preventing patients from 
dropout [4]. However, long-term use of benzodiazepines 
should be avoided because they elicit cognitive dysfunc-
tion, tolerance, dependence, and increase the risk of 
dementia in patients with MDD [5, 6], although a recent 
study has reported negative findings for the relationship 
between benzodiazepine use and the risk of dementia 
[7]. Therefore, it is important to establish a strategy for 
improving depression without using benzodiazepines 
from an early stage.
Mirtazapine is recognized as one of the first-line anti-
depressants for the treatment of MDD in addition to 
other antidepressants including selective serotonin reup-
take inhibitors (SSRIs) [8, 9]. Mirtazapine has a unique 
pharmacological profile with not only α2-adrenaline 
receptor antagonist activity but also histamine H1 and 
serotonin (5-HT)2A receptor antagonism, and it has hyp-
notic-like effects compared to the SSRIs and other first-
line antidepressants [10]. In addition, mirtazapine has 
5-HT2c receptor antagonist activity, which is thought to 
be effective in the treatment of anxiety [11]. Moreover, it 
has been reported that the onset of clinical antidepres-
sant responses to mirtazapine is faster than the onset 
with SSRIs [12, 13]. Considering that the actions of mir-
tazapine include hypnotic-like and fast-acting antidepres-
sant effects, we hypothesized that selecting mirtazapine 
over other antidepressants including SSRIs as the first 
choice for a current depressive episode could reduce ben-
zodiazepine use in patients with MDD.
Therefore, the primary purpose of this study was 
to determine whether treatment of current depres-
sive episodes with mirtazapine could reduce the use of 
benzodiazepine in patients with MDD more than the 
representative SSRIs, sertraline and paroxetine could. 
Furthermore, the secondary purpose of this study was to 
compare the efficacy and safety of these three antidepres-
sants in patients with MDD.
Accumulating preclinical and clinical studies have sug-
gested that the brain-derived neurotrophic factor (BDNF) 
plays an important role in the pathophysiology of MDD 
and serum levels of BDNF may have the relationship 
with clinical responses to treatments for depression [14]. 
Moreover, recent studies have shown that serum levels of 
mature BDNF and proBDNF, which is a precursor form 
of mature BDNF, are successfully measured separately 
[15–17]. Furthermore, mature BDNF and proBDNF are 
reported to play different roles in neurophysiological 
functions via the tropomyosin receptor kinase B (TrkB) 
and p75 neurotrophin receptors, respectively [14, 18, 19]. 
Meta-analysis studies have shown that antidepressant 
treatments influence serum levels of BDNF in patients 
with MDD [20, 21]. However, the effects of antidepres-
sant treatments on serum levels of mature BDNF and 
proBDNF in patients who are depressed are not well 
known. Therefore, we also determined whether serum 
levels of mature BDNF and proBDNF could be potential 
biomarkers of clinical responses to antidepressant treat-
ments in patients with MDD.
Methods
Study design and participants
We conducted an open-label, randomized, and active-
controlled 24-week trial in outpatients with current 
depressive episodes in routine psychiatric practice set-
tings. The study participants were recruited from 13 sites 
in Japan, and the study was conducted from September 
2010 to March 2014. This study was approved by the 
Institutional Review Boards and Ethics Committees of all 
the participating institutes and was performed in accord-
ance with the ethical standards of the Helsinki Declara-
tion of 1975, as revised in 2013. The trial was registered 
with the Clinical Trials Registry of the University Hospi-
tal Medical Information Network (UMIN, Tokyo, Japan, 
registration number UMIN000004144). All subjects pro-
vided written informed consent for their participation in 
the study after the procedure had been fully explained to 
them.
The inclusion criteria for prospective participants were: 
(1) age 20–75 years; (2) diagnosed according to the Diag-
nostic and Statistical Manual of Mental Disorders, 4th 
Edition, Text Revision criteria for MDD; (3) a ≥12 total 
score on the 17-item Hamilton depression rating scale 
(HDRS) [22]; (4) considered to require antidepressant 
treatment based on the judgment of the consulting psy-
chiatrist. The exclusion criteria for participants were the 
following: (1) previous history of the use of mirtazapine 
or both sertraline and paroxetine; (2) pregnant or breast-
feeding; (3) at significant risk for suicide; (4) diagnosed 
with a primary condition including dementia as well as 
bipolar, obsessive–compulsive, or eating disorders, schiz-
ophrenia, or alcohol or substance dependence except for 
tobacco dependence; (5) experiencing any medical condi-
tions judged to render the patient ineligible to participate 
in the study.
Procedures
The participants in this study were treatment-seeking 
outpatients who personally visited each investigating 
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hospital or clinic to consult about their current depres-
sive symptoms. The participants were provided with 
the full details of the study modality and were informed 
that they were responsible for the usual consultation and 
medicine fees because the study was conducted in the 
routine psychiatric practice setting. The participants were 
randomly assigned to the mirtazapine or SSRIs groups in 
a 1:2 ratio. The computerized randomization program 
provided by EPS Associates Co., Ltd. (Tokyo, Japan) had 
a minimization algorithm with two prognostic factors, 
sex and sleep-related scores of the HDRS (i.e., low 0–3 or 
high 4–6). The investigators overseeing the SSRIs groups 
were free to choose either sertraline or paroxetine. If the 
participant had been taking other antidepressants before 
participating in this study, the drugs were tapered off 
during the first 4 weeks. The titration and tapering of the 
dosage of the investigational antidepressants were flex-
ible and based on the clinical judgment of each investiga-
tor throughout the study.
Furthermore, each investigator prescribed benzodiaz-
epines or benzodiazepine-like drugs such as zolpidem 
and zopiclone for insomnia or anxiety symptoms from 
the first day of the study after providing a sufficient expla-
nation of the risks involved including dependence and 
sedation. In principle, the investigators were to prescribe 
the designated drugs of benzodiazepines for insomnia 
and anxiety symptoms of the participants. At the same 
time, they were also free to prescribe other benzodiaz-
epines, zolpidem or zopiclone other than the designated 
benzodiazepines on the basis of the clinical judgement of 
each investigator-in-charge. In addition, the participants 
were provided with directions on how to administer the 
benzodiazepines according to the drug prescribing infor-
mation and the original study instructions. Alternatively, 
the investigators were also allowed to avoid prescribing 
benzodiazepines when the patients did not wish to take 
them. The patients were directed to take the benzodi-
azepines when needed, similar to the pill-in-the-pocket 
approach according to each patient’s judgment and not 
on a fixed schedule. The participants were required to 
maintain a daily record of taking the medication using 
specific notebooks, which were copied at every visit 
to check their compliance with the medication use and 
the use of the benzodiazepines. The patients were not 
informed that taking the benzodiazepines was one of the 
clinical outcomes of the study. Furthermore, they were 
provided with the usual medical consultation but were 
not treated with the specific psychotherapy for the pur-
pose of reducing benzodiazepine use.
Blood samples were collected between 10:00 a.m. and 
4:00  p.m. at baseline and weeks 6, 12, and 24 to meas-
ure the serum mature BDNF and proBDNF levels. The 
serum samples were rapidly delivered to the Department 
of Psychiatry, Chiba University Graduate School of Medi-
cine in anticoagulant tubes at 4 °C and stored at −80 °C 
until analyzed.
Measurements of serum mature and precursor proBDNF 
levels
The mature BDNF and precursor proBDNF levels were 
measured using a human proBDNF enzyme-linked 
immunosorbent assay (ELISA) kit (Biosensis, Thebarton, 
SA, Australia) and the human mature BDNF ELISA Kit 
(Aviscera Bioscience, Santa Clara, CA, USA). All experi-
ments were performed in duplicate according to the 
manufacturer’s instructions. The optical density of the 
resulting reaction solutions in each well was measured 
using an automated microplate reader (Emax, Molecular 
Devices, Sunnyvale, CA, USA).
Assessments of clinical outcomes
The primary outcome of this study was the proportion of 
patients using benzodiazepines, denoted as “benzodiaz-
epine users”, at weeks 6, 12, and 24, which was compared 
for the two (mirtazapine and SSRIs) or three (mirtazap-
ine, sertraline, and paroxetine) investigational groups. 
The benzodiazepine users and non-users were defined 
as patients who took benzodiazepine drugs once or more 
during the 1-week period prior to each assessment points 
(6, 12 and 24 weeks) or did not, respectively. Based on the 
frequencies of benzodiazepine use, the participants were 
distinguished into non-use, 1–6 days per week usage, and 
everyday usage and benzodiazepine users were defined 
as those in the 1–6  days per week usage or daily usage 
categories. To clarify the effect of each antidepressant on 
the use of benzodiazepines, we determined the number 
of patients in each group who were prescribed benzo-
diazepines from the first prescription day of the study 
and compared the proportion of benzodiazepine users 
between the groups. Therefore, the patients who did 
not want benzodiazepine prescriptions on the first day 
of the study were excluded from the primary outcome 
assessment.
The secondary outcomes were the efficacy and safety 
assessments of each antidepressant treatment, which 
were compared between the groups of patients pre-
scribed benzodiazepines on the first day, and between 
the groups regardless of benzodiazepine prescription 
using an intent-to-treat analysis. To assess the sever-
ity of depressive symptoms, we used the HDRS and 
defined patients showing a ≥50  % reduction in HDRS 
scores from baseline to assessment day as respond-
ers, and those who did not as non-responders. We also 
assessed the self-reported inventory of depression using 
the Zung self-rating depression scale (SDS) questionnaire 
[23]. To assess the severity of sleep disturbances, we used 
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the Athens insomnia scale (AIS) [24] and also adminis-
tered the clinical global impressions-severity (CGI-S) 
scale [25]. The HDRS, SDS, AIS, and CGI-S scores were 
measured at baseline and weeks 1, 2, 6, 12, and 24. For 
the safety assessments, we collected information on all 
the adverse events (AEs) observed during this study, 
which were defined as serious AEs such as those leading 
to death, life-threatening conditions, hospitalizations, or 
persistent disability.
Assessments of relationship between clinical responses 
and serum BDNF levels
To explore the clinical applicability of serum mature 
BDNF and proBDNF measurements as biomarkers in 
depression treatment, we specifically examined the rela-
tionship between the clinical responses to antidepressant 
treatments and serum BDNF levels in both antidepres-
sant groups using the following two approaches. One 
approach involved examining whether the measured 
baseline serum levels of mature BDNF and proBDNF 
would be adequate predictors of clinical responses to 
antidepressant treatments during the acute phase (e.g., 
6–8  weeks) of depression treatment. Specifically, we 
examined the baseline levels of serum mature BDNF and 
proBDNF between responders and non-responders who 
were assessed at week 6. The other strategy was to evalu-
ate the long-term effectiveness of antidepressant treat-
ments by examining the associated changes in serum 
levels of mature BDNF and proBDNF in responders who 
achieved clinical responses by the final assessment day, 
week 24. Moreover, we also examined the ratio of the lev-
els of mature BDNF and proBDNF according to a previ-
ous study [17].
Statistical analyses
The analyses of the primary outcome were performed in 
proportions of the benzodiazepine users at weeks 6, 12, 
and 24, between the groups of patients who were pre-
scribed benzodiazepines from the first study day using a 
two-tailed Chi-square test or the Fisher’s exact test.
The analyses of the efficacy outcomes were conducted 
on an intent-to-treat basis, and using a linear mixed-
effects model for repeated measures (MMRM) with 
treatment group, week, and treatment group-by-week 
interaction as fixed effects and subject as a random effect. 
The Bonferroni adjustment was used for the multiple 
comparisons. The safety analyses were performed for the 
three groups of patients who took at least one dose of the 
prescribed antidepressant.
We used parametric tests to analyze the data of the 
serum mature BDNF levels while non-parametric tests 
were used for the serum proBDNF levels and the ratio of 
serum mature BDNF and proBDNF levels because these 
data did not follow a normal distribution although that 
of the mature BDNF did. We conducted an independ-
ent t test or the Mann–Whitney U test to compare the 
baseline levels of BDNF between the responders and 
non-responders. We used a repeated analysis of variance 
(ANOVA) for the serum mature BDNF levels while the 
Friedman’s test was used for the proBDNF levels and the 
ratio of both proteins to examine the long-term effects 
of antidepressant treatments on continuous changes in 
serum BDNF levels.
A P  <  0.05 was considered statistically significant in 
all analyses, which were conducted using the statistical 
package for the social sciences (SPSS) version 23.0 (IBM, 
NY, US).
We expected the proportions of benzodiazepine users 
to be 30.0 and 60.0 % in mirtazapine and SSRIs groups, 
respectively, according to a previous study [1] with an 
alpha error and power of 5.0 and 80.0  %, respectively. 
The total sample size of 120 participants was estimated 
with a consideration of a 20.0 % withdrawal. We allowed 
this study to be completed ahead of schedule when the 
result of the primary outcome was obviously confirmed 
by an interim analysis that was used to detect the differ-
ence in the proportions of benzodiazepine users at week 
6 between the groups, which showed that the analysis 
achieved a P < 0.001 in the Chi-square test.
Results
Participants and clinical course outline
Of the 368 patients screened, 81 were enrolled in this 
study (Fig.  1). We perform an interim analysis of the 
data of 77 participants (Table  1) who were ready to be 
assessed by week 6 and subsequently terminated par-
ticipant recruitment. The termination was instituted 
because we confirmed that the primary outcome results 
of the analysis had achieved a P < 0.001, and the propor-
tions of benzodiazepine users in the mirtazapine and 
SSRIs groups were clearly distinct from each other. This 
indicated that we required a lower sample size than we 
originally expected.
Of the 18 patients assigned to receive paroxetine, ten 
and eight were prescribed the standard and controlled-
release (CR) tablets, respectively. The daily mean peak 
doses of the antidepressants in this study were 27. 
2 ± 11.8, 73.4 ± 28.4, 24.0 ± 8.0, and 37.5 ± 10.8 mg in 
the mirtazapine and sertraline groups as well as paroxe-
tine standard and paroxetine CR subgroups, respectively. 
The dose ranges of the mirtazapine, sertraline, paroxetine 
standard, and paroxetine CR antidepressants were as fol-
lows: 15.0–45.0, 25–100, 10–40, and 25–50 mg, respec-
tively. Table 2 shows the breakdown of benzodiazepines 
prescribed to the 65 patients who were prescribed them 
from prescription day 1.
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Completed follow-up at 24-week, n = 12 (44.4%)    
Prescribed BZs at the first visit, n = 8 (29.6%)
Not prescribed BZs at the first visit, n = 4 (14.8%)
SSRIs group, n = 50
Sertraline, n = 32 (64.0%) 
Prescribed BZs at the first visit, n = 28 (56.0%)
Not prescribed BZs at the first visit, n = 4 (8.0%)
Paroxene, n = 18 (36.0%)
Prescribed BZs at the first visit, n = 17 (34.0%)
Not prescribed BZs at the first visit, n = 1 (2.0%)
Assessed for eligibilityn = 368 
Randomized n = 81
Excluded n = 287
Did not meet inclusion criteria, n = 198 (69.0%)
Declined to parcipate, n = 68 (23.7%)
Other reasons, n = 21 (7.3%)
Completed follow-up at 24-week, n = 23 (46.0%)
Prescribed BZs at the first visit, n = 22 (44.0%)  
Not prescribed BZs at the first visit, n = 1 (2.0%)   
Sertraline treatment, n = 16 (32.0%)
Prescribed BZs at the first visit, n = 15 (30.0%)
Not prescribed BZs at the first visit, n = 1 (2.0%)
Paroxene treatment, n = 7 (14.0%)
Prescribed BZs at the first visit, n = 7 (14.0%)
Not prescribed BZs at the first visit, n = 0 (0.0%)
Withdrawal by the first 2 weeks, n = 8 (29.6%)
due to treatment-emergent AEs, n = 6 (22.2%)
lost to follow-up, n = 1 (3.7%)
withdrew consent to parcipaon, n = 1 (3.7%)   
Withdrawal by the first 2 weeks, n = 12 (24.0%)
Sertraline, n = 7 (14.0%)
due to treatment-emergent AEs, n = 2 (4.0%)
lost to follow-up, n = 3 (6.0%)
not adhering to treatment, n = 1 (2.0%)
hospitalizaon due to depression deterioraon, n = 1 (2.0%)   
Paroxene, n = 5 (10.0%)
due to treatment-emergent AEs, n = 2 (4.0%)
lost to follow-up, n = 2 (4.0%)
not adhering to treatment, n = 1 (2.0%)
Mirtazapine group, n = 27 
Prescribed BZs at the first visit, n = 20 (74.1%)
Not prescribed  BZs at the first visit, n = 7 (25.9%)
Assigned to SSRIs n = 54
Not prescribed SSRIs used in 
this study, n = 4 (7.4%)
Withdrawal from 2 weeks to the final visit, n = 7 (25.9%)
due to treatment-emergent AEs, n = 1 (3.7%)
lost to follow-up, n = 4 (14.8%)
their own intenons due to their recoveries, n = 1 (3.7%)
due to depression deterioraon, n = 1 (3.7%)
Withdrawal from 2 weeks to the final visit, n =  15 (30.0%)
Sertraline, n = 9  (18.0%)
their own intenons due to their recoveries, n = 1 (2.0%) 
lost to follow-up, n = 4 (8.0%)
due to not responding to treatment, n = 3 (6.0%)
withdrew consent to parcipaon, n =1 (2.0%) 
Paroxene, n = 6 (12.0%)
due to treatment-emergent AEs except for mania, n = 1 (2.0%)
due to manic symptoms, n = 2 (4.0%)
lost to follow-up, n = 1 (2.0%)
due to not responding to treatment, n = 2 (4.0%)
Assigned to mirtazapinen = 27
Fig. 1 Study flowchart. AE adverse event, BZ benzodiazepine, SSRI selective serotonin reuptake inhibitor
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Primary outcome: group proportions of benzodiazepine 
users
Table  3 shows the frequencies of the benzodiazepine 
users for the groups at each assessment point. As shown 
in Fig. 2, the percentage of benzodiazepine users at week 
6 in the mirtazapine group (21.4  %) was significantly 
lower than that in the SSRIs group (81.8 %, Fig. 2a). Sim-
ilarly, the percentage of benzodiazepine users at weeks 
12 and 24 was significantly lower in the mirtazapine 
group (11.1 and 12.5 %) than it was in the SSRIs group 
(85.7 and 81.8 %, Fig. 2b, c), respectively. Comparing the 
three antidepressant groups, the percentage of benzodi-
azepine users in the mirtazapine group was significantly 
lower than that sertraline and paroxetine groups were at 
weeks 6, 12, and 24 (Fig.  3a–c). Conversely, there were 
no significant differences in the percentages of benzodi-
azepine users between the mirtazapine and SSRIs groups 
at weeks 1 and 2 (52.9 vs. 72.1 and 53.3 vs. 66.7  %, 
respectively).
Table 1 Patient characteristics at baseline
SSRI selective serotonin reuptake inhibitor, SD standard variation, HDRS 17-item Hamilton depression rating scale, SDS Zung self-rating depression scale, AIS Athens 
insomnia scale, CGI-S clinical global impressions-severity
a Unpaired t test or Mann–Whitney U test
b One-way analysis of variance (ANOVA) or Kruskal–Wallis test
c Chi-square test or Fisher exact test










Male patients, n (%) 18 (66.7) 32 (64.0) nsc 20 (62.5) 12 (66.7) nsc
Age, mean (SD), years 38.9 (10.5) 40.4 (13.8) nsa 39.7 (13.3) 41.7 (14.9) nsb
Age at onset, mean (SD), years 38.1 (10.5) 39.3 (13.1) nsa 39.0 (12.5) 39.8 (14.5) nsb
Duration of illness, median [quartiles], week 30.0 [8.0–104.0] 20.0 [12.0–71.0] nsa 20.0 [8.0–58.5] 19.0 [12.0–117.0] nsb
Duration of current episode, median [quartiles], week 12.0 [7.0–40.0] 12.0 [8.0–34.0] nsa 14.0 [7.3–44.0] 12.0 [12.0–21.0] nsb
Depressive episodes nsc nsc
 Single, n (%) 22 (81.5) 42 (84.0) 28 (87.5) 14 (77.8)
 Recurrent, n (%)d 5 (18.5) 8 (16.0) 4 (12.5) 4 (22.2)
Past history of using any psychiatric services, n (%) 4 (14.8) 15 (30.0) nsc 11 (34.4) 4 (22.2) nsc
Past history of any psychotropic medication, n (%) 11 (40.7) 18 (36.0) nsc 14 (43.8) 4 (22.2) nsc
Treatments of the current episode, n (%) 4 (14.8) 5 (10.0) nsc 5 (15.6) 0 (0.0) nsc
Antidepressant treatment of the current episode, n (%) 3 (11.1) 3 (6.0) nsc 3 (9.4) 0 (0.0) nsc
Benzodiazepine treatment of the current episode, n (%) 1 (3.7) 1 (2.0) nsc 1 (3.1) 0 (0.0) nsc
HDRS, mean (SD) 23.0 (5.2) 23.1 (6.1) nsa 23.2 (6.2) 22.9 (6.0) nsb
SDS, mean (SD) 55.9 (5.4) 57.9 (7.8) nsa 57.9 (7.4) 57.9 (7.1) nsb
AIS, mean (SD) 11.2 (3.7) 12.9 (4.4) nsa 12.8 (4.3) 13.1 (4.7) nsb
CGI-S, median [quartiles] 4.0 [4.0–5.0] 4.0 [4.0–5.0] nsa 4.5 [4.0–5.0] 4.0 [4.0–5.0] nsb
Table 2 Breakdown of prescribed benzodiazepines
a Patients prescribed benzodiazepines at baseline (day 1) were only counted in 












 Brotizolam 12 22 9 13
 Estazolam 1 0 0 0
 Flunitrazepam 0 5 4 1
 Nitrazepam 1 1 1 0
 Rilmazafone 0 1 1 0
 Triazolam 0 4 3 1
 Zopiclone 0 1 1 0
 Zolpidem 1 0 0 0
As anxiolytics
 Alprazolam 2 7 1 6
 Bromazepam 0 5 5 0
 Etizolam 2 5 5 0
 Clotiazepam 0 2 2 0
 Lorazepam 7 16 9 7
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Efficacy
Regardless of whether the participants received benzo-
diazepine prescriptions from day 1, the average HDRS, 
SDS, AIS, and CGI-S total scores for each group were 
significantly decreased compared with those at the base-
line, as determined using the MMRM (P < 0.05). Table 4 
shows the sequential measurements of the efficacy out-
comes for all participants. The difference in the changes 
in the HDRS scores were not statistically significant 
between the mirtazapine and SSRIs groups (F  =  0.37, 
df  =  1, 78; mean difference, 95  % confidence interval 
[CI] −0.78 [–3.31 to 1.76], P = 0.54) or among the three 
groups (F = 0.49, df = 2, 76, P = 0.62). In addition, there 
was no statistical difference in the changes in the AIS and 
CGI-S scores between the mirtazapine and SSRIs groups 
(AIS: F = 2.23, df = 1, 73; mean difference, 95 % CI −1.32 
[–3.07 to 0.44], P  =  0.14; CGI-S: F  =  1.11, df  =  1, 78; 
mean difference, 95 % CI −0.19 [–0.56 to 0.17], P = 0.30), 
and among the three groups (AIS: F = 3.10, df = 2, 70, 
P = 0.051; CGI-S: F = 0.80, df = 2, 76, P = 0.45). Regard-
ing the SDS, the difference in the changes in SDS scores 
was not statistically significant between the mirtazap-
ine and SSRIs groups (F = 3.40, df = 1, 79; mean differ-
ence, 95 % CI −3.30 [−6.86 to 0.26], P = 0.069); however, 
there was a significant difference among the three groups 
(F = 3.29, df = 2, 76, P = 0.043). Specifically, there were 
significantly different changes in the SDS scores between 
the mirtazapine and paroxetine groups (mean difference 
95 % CI −5.74 [−11.22 to −0.25], P = 0.038), indicating 
that the SDS scores of the mirtazapine group had 
improved more significantly than those of the paroxetine 
group. Similarly, the analyses of the data of patients who 
were prescribed benzodiazepines from day 1 revealed 
that the differences in the changes from the baseline 
HDRS, AIS, and CGI-S scores were not statistically sig-
nificant between the mirtazapine and SSRIs groups 
as well as among the three groups (data not shown). In 
contrast to the analysis of the data of all the participants, 
there were no significant differences in the HDRS, AIS, 
and CGI-S (data not shown) as well as the SDS between 
the mirtazapine and SSRIs groups (SDS: F  =  3.05, 
df = 1, 67, P = 0.085) and among the three groups (SDS: 
F = 2.45, df = 2, 64, P = 0.095) in the patients who were 
prescribed benzodiazepines from day 1.
Safety analysis
Table 5 shows the details of all treatment-emergent AEs 
observed in this study. The AEs that led to the discon-
tinuation of study participation appeared within the 
first 2 weeks except for the case of abnormal liver func-
tion tests, which was observed at week 6. However, the 
affected patients recovered after withdrawing from the 
study except for the patients with the SAEs. The analysis 
of the incidence rate of AEs revealed that the proportions 
of the patients with any AEs differed among the three 
antidepressant groups (χ2  =  12.5, df  =  2, P  =  0.0019). 
Specifically, the percentage of patients with any AEs was 
significantly lower in the sertraline (7/32, 21.9 %) group 
Table 3 Frequencies of benzodiazepine use in participants
SSRI selective serotonin reuptake inhibitor
a Patients prescribed benzodiazepines at baseline (day 1) were only counted in numbers in this table
Baselinea Week 1 Week 2 Week 6 Week 12 Week 24
Mirtazapine n = 20 n = 17 n = 15 n = 14 n = 9 n = 8
Non-use, n (%) 8 (47.1) 7 (46.7) 11 (78.6) 8 (88.9) 7 (87.5)
1–6 days per week, n (%) 5 (29.4) 4 (26.7) 1 (7.1) 0 (0.0) 0 (0.0)
Every day, n (%) 4 (23.5) 4 (26.7) 2 (14.3) 1 (11.1) 1 (12.5)
SSRIs n = 45 n = 43 n = 42 n = 33 n = 28 n = 22
Non-use, n (%) 12 (27.9) 14 (33.3) 6 (18.2) 4 (14.3) 4 (18.2)
1–6 days per week, n (%) 15 (34.9) 8 (19.0) 12 (36.4) 9 (32.1) 4 (18.2)
Every day, n (%) 16 (37.2) 20 (47.6) 15 (45.5) 15 (53.6) 14 (63.6)
Sertraline n = 28 n = 26 n = 26 n = 22 n = 19 n = 15
Non-use, n (%) 7 (26.9) 9 (34.6) 5 (22.7) 3 (15.8) 3 (20.0)
1–6 days per week, n (%) 8 (30.8) 4 (15.4) 7 (31.8) 5 (26.3) 2 (13.3)
Every day, n (%) 11 (42.3) 13 (50.0) 10 (45.5) 11 (57.9) 10 (66.7)
Paroxetine n = 17 n = 17 n = 16 n = 11 n = 9 n = 7
Non-use, n (%) 5 (29.4) 5 (31.3) 1 (9.1) 1 (11.1) 1 (14.3)
1–6 day per week, n (%) 7 (41.2) 4 (25.0) 5 (45.5) 4 (44.4) 2 (28.6)
Every day, n (%) 5 (29.4) 7 (43.8) 5 (45.5) 4 (44.4) 4 (57.1)
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than in the mirtazapine (16/27, 59.3 %, χ2 = 8.6, df = 1, 
P = 0.034) and paroxetine (12/18, 66.7 %, χ2 = 9.8, df = 1, 
P = 0.0017) groups.
Relationship between clinical responses and serum BDNF 
levels
Table  6 shows the comparisons of the baseline levels of 
mature BDNF, proBDNF, and their ratios between the 
responders and non-responders in both groups at week 
6. There were no significant differences in the baseline 
levels of each BDNF protein between the two groups 
(Table 6).
Table 7 shows the long-term effectiveness of the anti-
depressant treatments on serum BDNF levels in 27 
responders of both groups on the final assessment day 
at week 24. Of the 35 patients who completed the study, 
there were technical failures in the samples of five while 
three did not achieve a clinical response by week 24. 
The serum levels of the mature BDNF decreased signifi-
cantly between weeks 6 and 12 from the baseline levels 
but the change did not persist (Table 7). Furthermore, the 
serum proBDNF levels of the responders who achieved 
clinical responses by week 24 were statistically signifi-
cantly decreased when compared to the baseline levels 
(Table 7).
Discussion
Three interesting results in this study are of particular 
significance and worth expounding. First, among the 
patients with depression who were prescribed both an 
antidepressant and benzodiazepines from the beginning 
of the treatment, our results showed that there was a sig-
nificantly smaller proportion of benzodiazepine users in 
the mirtazapine treatment group than there was in the 
SSRIs treatment group. However, the efficacy of mir-
tazapine in treating depression was not different from 
that of the SSRIs. Second, the safety assessment revealed 
that the proportion of patients who experienced treat-
ment-emergent AEs was significantly lower in the sertra-



































































Benzodiazepine Users at Week 12






































Fig. 2 Proportions of benzodiazepine users in mirtazapine and selective serotonin reuptake inhibitors (SSRIs) groups. Numbers in parentheses above 
bars are actual numbers of benzodiazepine users and group participants assessed each week. Benzodiazepine users are defined as patients who 
took benzodiazepine drugs once or more during the 1-week period prior to each assessment point (weeks 6, 12, and 24). Patients were prescribed 
benzodiazepines from study day 1. P values are based on analyses of Chi-square (a) and Fisher’s exact test (b, c). SSRI selective serotonin reuptake 
inhibitor
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groups. Third, the present study showed that the serum 
proBDNF levels of the responders who achieved clini-
cal responses in both antidepressant groups at the final 
assessment day, at week 24, were significantly decreased 
compared to the baseline levels, while the serum mature 
BDNF levels significantly decreased from week 6 to 12, 
but only temporarily, and this effect did not persist till 
week 24.
The results of our analysis revealed that among the 
depressed patients prescribed both an antidepressant 
and benzodiazepines at the beginning of treatment, there 
was a significantly smaller proportion of benzodiaze-
pine users that were treated with mirtazapine than were 
treated with SSRIs. However, the efficacy of mirtazapine 
in depression treatment was not different from that of 
the SSRIs. These results are compatible with our hypoth-
esis. A previous meta-analysis of the discontinuation of 
benzodiazepine use demonstrated that the effective strat-
egies are mainly psychological interventions combined 
with regimens such as a gradual reduction in the dose of 
prescribed benzodiazepines [26–28]. Although numer-
ous studies have indicated the benefits of discontinuing 
benzodiazepine use in pharmacotherapy, effective phar-
macological interventions have not yet been established 
to replace them [26–29]. Although restricting or discon-
tinuing the use of benzodiazepines is strongly recom-
mended in the treatment of depression, this has been 
challenging to achieve in routine clinical practice [26]. 
Therefore, antidepressant treatments without benzodiaz-
epines from the acute phase or the first stage of treatment 
of major depression are considered useful for reducing 
the number of benzodiazepine users. Furthermore, the 
findings of the present study have identified the antide-





















































































































Fig. 3 Proportions of benzodiazepine users in three antidepressants groups. Numbers in parentheses above bars are actual number of benzodiaze-
pine users and group participants assessed each week. Benzodiazepine users are defined as patients who took benzodiazepine drugs once or more 
during the 1-week period prior to each assessment point (weeks 6, 12, and 24). Patients were prescribed benzodiazepines from study day 1. We 
analyzed differences in the proportions in two groups using Chi-square test at week 6 (a) and Fisher’s exact test at week 12 and 24 (b, c), after the 
analyses were conducted among the three groups using Chi-square test at week 6 and the Fisher’s exact test at week 12 and 24. P values are based 
on analyses of Chi-square (a) and the Fisher exact test (b, c)
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influence the persistent use of benzodiazepines in the 
treatment of patients with MDD. Specifically, our results 
suggest that prescribing mirtazapine as the first antide-
pressant to be administered could potentially prevent 
patients who are depressed from having to continuously 
take benzodiazepines. Further comprehensive, double-
blind studies would be required to confirm this finding.
The efficacy analysis of this study revealed there were 
no statistically significant differences in the changes in 
the HDRS scores between the mirtazapine and the SSRIs 
groups as well as between the three groups. These results 
are consistent with the findings of a meta-analysis study 
of mirtazapine versus other antidepressants including 
SSRIs [13]. Additionally, the mirtazapine group improved 
more than the paroxetine group did in the change in SDS 
scores. It is difficult to explain the discrepancy between 
the HDRS and SDS scores of the mirtazapine and par-
oxetine groups in this study because two meta-analysis 
studies previously demonstrated a lack of difference in 
the efficacy of mirtazapine and paroxetine [13, 30]. A 
plausible explanation is that the paroxetine group had a 
smaller size than the mirtazapine group did, which might 
have influenced the results. The efficacy of ameliorating 
sleep disturbances, as determined by the AIS assessment, 
showed no statistically significant differences between 
the groups. Considering that the efficacy of mirtazapine 
in treating depressive symptoms and sleep disturbances 
is not different from that of the SSRIs, the present find-
ings could support mirtazapine as the first choice for the 
treatment of major depression because of its advantage of 
decreasing the benzodiazepine requirement compared to 
the SSRIs.
The safety analysis demonstrated that the proportion of 
patients who experienced treatment-emergent AEs was 
significantly lower in the sertraline group than it was in 
the mirtazapine and paroxetine groups. These results are 
consistent with the findings of a previous meta-analysis 
study [31] that demonstrated the high tolerability of ser-
traline and relatively low tolerability of mirtazapine and 
paroxetine in patients with MDD.
Focusing on the AEs of mirtazapine, our results showed 
that sedation, including somnolence, very likely caused 
the discontinuation of the drug in the early stage of the 
treatment of major depression. Although it has been 
reported that the effectiveness of mirtazapine on sleep 
disturbance appears very quickly [32], sedation caused by 
mirtazapine occurs with high frequency (50 % or more) 
[9]. The improvement of sleep disturbance and sedation 
Table 4 Sequential measurements of clinical efficacy outcomes
All values are based on estimated marginal means using a linear mixed effects model for repeated measures data
SSRI selective serotonin reuptake inhibitor, HDRS 17-item Hamilton depression rating scale, SDS Zung self-rating depression scale, AIS Athens insomnia scale, SE 
standard error
Variables Baseline Week 1 Week 2 Week 6 Week 12 Week 24
Estimated marginal means (SE)
HDRS
 Mirtazapine 23.0 (1.2) 19.0 (1.3) 15.5 (1.3) 9.6 (1.4) 9.3 (1.5) 5.9 (1.6)
 SSRIs 23.1 (0.9) 19.2 (0.9) 16.9 (0.9) 12.9 (1.0) 9.5 (1.0) 5.4 (1.1)
  Sertraline 23.2 (1.1) 19.1 (1.2) 16.3 (1.1) 12.1 (1.2) 8.7 (1.3) 5.3 (1.4)
  Paroxetine 22.9 (1.5) 19.4 (1.5) 17.8 (1.5) 14.6 (1.7) 11.2 (1.8) 5.8 (2.0)
SDS
 Mirtazapine 56.0 (1.7) 52.4 (1.8) 46.6 (1.8) 44.0 (1.9) 43.7 (2.1) 38.0 (2.2)
 SSRIs 57.6 (1.3) 54.8 (1.3) 52.8 (1.3) 48.7 (1.4) 44.9 (1.5) 41.8 (1.6)
  Sertraline 57.4 (1.6) 54.1 (1.7) 51.2 (1.6) 47.2 (1.7) 42.4 (1.8) 40.3 (1.9)
  Paroxetine 57.9 (2.1) 56.1 (2.1) 55.0 (2.1) 51.4 (2.3) 49.8 (2.5) 44.5 (2.8)
AIS
 Mirtazapine 11.5 (0.9) 8.4 (0.9) 6.6 (0.9) 5.8 (1.0) 6.8 (1.1) 5.0 (1.1)
 SSRIs 12.9 (0.6) 10.2 (0.6) 9.3 (0.6) 7.5 (0.7) 6.6 (0.7) 5.5 (0.8)
  Sertraline 12.8 (0.8) 10.0 (0.8) 8.1 (0.8) 6.9 (0.8) 5.3 (0.9) 4.6 (1.0)
  Paroxetine 13.1 (1.0) 10.5 (1.0) 11.3 (1.0) 8.8 (1.2) 9.2 (1.2) 7.2 (1.4)
CGI-S
 Mirtazapine 4.4 (0.2) 3.8 (0.2) 3.2 (0.2) 2.8 (0.2) 2.6 (0.2) 1.8 (0.2)
 SSRIs 4.3 (0.1) 4.0 (0.1) 3.6 (0.1) 3.1 (0.1) 2.7 (0.1) 2.1 (0.2)
  Sertraline 4.4 (0.2) 4.0 (0.2) 3.6 (0.2) 3.0 (0.2) 2.6 (0.2) 2.1 (0.2)
  Paroxetine 4.2 (0.2) 4.1 (0.2) 3.6 (0.2) 3.5 (0.2) 3.0 (0.3) 2.0 (0.3)
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Table 5 Summary of treatment-emergent adverse events (AEs)
AE adverse event, SAE serious adverse event
a Brain hemorrhage was unrelated to sertraline administration according to the diagnosis by the neurosurgeon. All AEs were treatment emergent
Mirtazapine, n = 27 Sertraline, n = 32 Paroxetine, n = 18
n (%) n (%) n (%)
Total number of patients with AEs 16 (59.3) 7 (21.9) 12 (66.7)
Serious AEs (SAEs) 0 (0.0) 2 (6.3) 0 (0.0)
Brain hemorrhagea 0 (0.0) 1 (3.1) 0 (0.0)
Hospitalization due to depression deterioration 0 (0.0) 1 (3.1) 0 (0.0)
AEs leading to discontinuation except for SAEs 7 (25.9) 1 (3.1) 5 (27.8)
Sedation including somnolence 3 (11.1) 0 (0.0) 0 (0.0)
Insomnia 1 (3.7) 0 (0.0) 0 (0.0)
Abnormal liver function test 1 (3.7) 0 (0.0) 0 (0.0)
Eruption 1 (3.7) 0 (0.0) 0 (0.0)
Dysgeusia 1 (3.7) 0 (0.0) 0 (0.0)
Nausea 0 (0.0) 1 (3.1) 1 (5.6)
Sexual dysfunction (erection failure) 0 (0.0) 0 (0.0) 1 (5.6)
Mania 0 (0.0) 0 (0.0) 2 (11.1)
Panic attack 0 (0.0) 0 (0.0) 1 (5.6)
Specific symptoms of AEs except for SAEs
 Sedation including somnolence 9 (33.3) 0 (0.0) 3 (16.7)
 Insomnia 2 (3.7) 1 (3.1) 0 (0.0)
 Akathisia 1 (3.7) 0 (0.0) 2 (11.1)
 Irritability 1 (3.7) 1 (3.1) 1 (5.6)
 Mania 0 (0.0) 0 (0.0) 2 (11.1)
 Weight increased 3 (11.1) 0 (0.0) 0 (0.0)
 Increased appetite 1 (3.7) 0 (0.0) 0 (0.0)
 Headache 0 (0.0) 0 (0.0) 2 (11.1)
 Dizziness 0 (0.0) 0 (0.0) 1 (5.6)
 Nausea 1 (3.7) 5 (15.6) 4 (22.2)
 Fatigue 3 (11.1) 0 (0.0) 2 (11.1)
 Eruption 1 (3.7) 0 (0.0) 0 (0.0)
 Abnormal liver function test 1 (3.7) 0 (0.0) 0 (0.0)
 Dysgeusia 1 (3.7) 0 (0.0) 0 (0.0)
 Sexual dysfunction (erection failure) 0 (0.0) 0 (0.0) 1 (5.6)
 Hyperhidrosis 0 (0.0) 0 (0.0) 2 (11.1)
 Constipation 0 (0.0) 0 (0.0) 1 (5.6)
Table 6 Baseline serum brain-derived neurotrophic factor (BDNF) levels of responders and non-responders at week 6
Responders and non-responders were assessed at week 6
BDNF brain-derived neurotrophic factor, SD standard deviation
a Ratio is serum level of mature BDNF (pg/mL) divided by that of proBDNF (pg/mL) in each individual. Serum mature BDNF levels were analyzed using Student t test. 
Serum proBDNF and ratio of mature BDNF/proBDNF were analyzed using Mann–Whitney U test
Responders, n = 24 Non-responders, n = 29 Statistics P
Levels at baseline
 Mature BDNF (ng/mL), mean (SD) 12.8 (3.8) 13.4 (3.4) t = −0.67, df = 51 0.51
 ProBDNF (pg/mL), median [quartiles] 607.5 [84.4, 5158.3] 135.0 [45.6, 2803.5] Z = −1.3 0.18
 Ratio of mature BDNF/proBDNFa 25.7 [2.3, 146.8] 105.7 [4.7, 309.2] Z = −1.3 0.21
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with mirtazapine treatment is thought to be inextricably 
linked. Therefore, mirtazapine as the first-choice agent 
in depression treatment could be expected to effectively 
treat depression without the use of benzodiazepines 
by its rapid onset of clinical action and improvement of 
sleep disturbance [12, 13, 32, 33]. However, it would be 
necessary to implement considerations and strategies to 
reduce the risk of early dropout due to sedation.
The present study showed that serum proBDNF lev-
els of the responders who achieved clinical responses in 
both antidepressant groups at the final assessment day 
were significantly decreased at week 24 compared to the 
baseline levels. Furthermore, the serum mature BDNF 
levels significantly decreased from week 6 to 12, but the 
change did not persist up to week 24. To the best of our 
knowledge, this is the first report to show the changes in 
serum levels of mature BDNF and proBDNF following 
antidepressant treatment in patients who are depressed 
and achieved clinical responses. A previous study by 
Yoshimura et  al. [16] reported there were no changes 
in the serum levels of mature BDNF and proBDNF in 
patients with MDD, who were administrated fluvoxam-
ine for 4 weeks. Our findings are inconsistent with their 
results, and a plausible reason is that the experimen-
tal conditions of these two studies differed. Specifically, 
our present study focused on clinical responders, and 
the duration was 24  weeks, which differed from that of 
Yoshimura et  al. [16] that had a 4-week duration. The 
present results may not have provided practical bio-
markers as predictors of clinical responses because the 
serum levels of mature BDNF changed erratically and the 
decrease in serum proBDNF levels was too slow. How-
ever, our present findings may contribute to the under-
standing of the physiological roles of mature BDNF and 
proBDNF in the timing of the clinical responses and 
effectiveness of antidepressant treatments in patients 
with MDD. The physiological mechanisms and dynamics 
of serum mature BDNF and proBDNF levels in mood dis-
orders such as major depression and bipolar disorder are 
still unclear and remain to be elucidated. Furthermore, 
a recent meta-analysis reports that the peripheral blood 
levels of BDNF in patients with bipolar disorder with 
manic and depressive episodes are decreased, but those 
with euthymia are not altered compared to healthy con-
trols [34]. In contrast, Södersten et al. [17] reported that 
the serum levels of mature BDNF are higher in patients 
with bipolar disorder than they are in the controls. Fur-
ther studies are needed to identify the effects of antide-
pressants on blood levels of mature BDNF and proBDNF 
using larger sample sizes, to clarify their physiological 
mechanisms in mood disorders such as major depression 
and bipolar disorder.
In addition, there were no differences in the level of 
mature BDNF, proBDNF, and the ratio of mature BDNF/
proBDNF at the baseline between the responders and 
non-responders assessed at week 6. Previous studies, 
which did not distinguish between mature BDNF and 
proBDNF, showed incongruous findings that serum 
BDNF levels would be useful as a predictor of responses 
to antidepressant treatments in patients who are 
depressed [35–37]. Our results do not support measuring 
mature BDNF and proBDNF at pre-treatment as a use-
ful predictor of responses to antidepressant treatment in 
patients with MDD.
There are four main limitations to this study, which are 
worth mentioning. First, as a prospective, randomized, 
open-label, blinded endpoint (PROBE) procedure, the 
investigators were aware of the primary endpoint in this 
study. Therefore, there was a possibility that the inves-
tigators emphasized to the patients the effect of mir-
tazapine on sleep disturbance. This could have led to a 
potential placebo effect on those who took mirtazapine. 
Furthermore, this issue is a technical inevitability in an 
open study. Therefore, a double-blind, randomized clini-
cal trial (RCT) would be needed to confirm our results. 
Second, the numbers of dropouts were too numerous 
to accurately assess the effects of antidepressant treat-
ments in this study. Regarding the pragmatic aspects of 
Table 7 Long-term changes in serum levels of brain-derived neurotrophic factor (BDNF) in responders at week 24
Serum mature BDNF levels were analyzed using repeated measure analysis of variance (ANOVA). Adjustment for multiple comparisons was Bonferroni. Serum 
proBDNF levels and ratio of mature BDNF/proBDNF levels were analyzed using Friedman’s test followed by Wilcoxon signed rank test
BDNF brain-derived neurotrophic factor, EMS estimated marginal means, SE standard error, CI confidence interval
a Mean differences in serum mature BDNF levels at week 6 (−1.4 ng/mL, SE = 0.5, 95 % CI −2.7 to –0.07, P = 0.035) and at week 12 (−0.8 ng/mL, SE = 0.3, 95 % CI 
−1.7 to −0.01, P = 0.045) were significantly decreased compared to the baseline levels
b Serum proBDNF levels at week 24 were significantly decreased compared to the baseline levels (Z = −2.4, P = 0.019). *P < 0.05, n = 27
Baseline Week 6 Week 12 Week 24 Statistics P
Mature BDNF (ng/mL), EMS (SE) 12.7 (0.7) 11.2 (0.7)a 11.8 (0.7)a 12.1 (0.7) F = 3.5, df = 2.4 0.027*
ProBDNF (pg/mL), median [quartiles] 634.7 [92.4, 5381.8] 507.9 [95.6, 4975.8] 484.5 [82.5, 4471.0] 463.5 [109.5, 4018.4]b χ2 = 8.5, df = 3 0.036*
Ratio of mature BDNF/proBDNF, 
median [quartiles]
22.7 [2.1, 135.6] 27.0 [2.3, 115.5] 29.3 [2.7, 127.8] 30.4 [3.1, 153.6] χ2 = 1.6, df = 3 0.67
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conducting clinical trials, Rutherford et al. [38] reported 
that the frequency of patient visits influences the drop-
out rate in antidepressant treatment [38]. The assessment 
intervals in this study were 1 week or more even in the 
first 4 weeks because the priority was to ensure a routine 
psychiatric practice setting was maintained above the 
experimental considerations. Previous survey studies of 
antidepressant prescriptions for treating depression in 
general clinical practice demonstrated that patients dis-
continue an initial antidepressant in the first 4 weeks at 
a rate of 26.2–42.4 % [39–42]. The present results of the 
dropout rate evaluation were similar to the previously 
reported rates in general clinical practice [39–42]. To 
elucidate the effectiveness of antidepressants on the con-
tinuous use of benzodiazepines further, the rate of visit 
frequencies of future studies should be higher than they 
were in this study. Third, sertraline and paroxetine were 
not randomized in this study. The patients randomly 
assigned to the SSRIs group were prescribed sertraline 
or paroxetine according to each investigator’s assessment 
and judgment. We incorporated a pragmatic trial design 
into real-life practice settings rather than an exploratory 
study design [43]. To clarify the findings of the present 
study, further studies that are strictly designed, such 
as a double-blind RCT, are necessary. Fourth, the sam-
ple size of this study was small and, therefore, we were 
unable to examine the potential applicability of the serum 
BDNF level as a biomarker of clinical antidepressant 
drug responses. Further studies with a larger sample size 
would be required to verify this.
Conclusions
This study showed the possibility of mirtazapine as the 
first-choice antidepressant for current depressive epi-
sodes by revealing its potential as an effective strategy to 
reduce the use of benzodiazepines in patients with major 
depression.
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